Data from a new study published in the journal Nature by the developer of the single-dose serum shows this: “The vaccine induces a strong immune response against the major virus variants.”
Johnson & Johnson’s single-dose Covid-19 vaccine induces a strong immune response Fight against virus variants Most concerned. As part of the Phase 1-2 COV1001 clinical trial, the results of a new study conducted by single-dose serum developers demonstrate this, and they examined the antibody and T cell levels of a group of vaccinated volunteers.
Analysis, published in natural, Thus expanding the information related to immunogenicity (the ability of the vaccine to induce an immune response), which so far only applies to the original virus strain (WA1/2020), expanding the assessment of the virus Alpha variants (B.1.1.7, formerly English), Beta (B.1.351, formerly South Africa), Gamma (P.1, formerly Brazil) and Epsilon (CAL.20C, formerly California).
Johnson & Johnson guards against the most dangerous variants
Specifically, the inspection showed that there were some differences in antibody response compared with the antibody response against WA1 / 2020 strains, especially the reduction of neutralizing antibodies against B.1.1351 and P.1 strains (lower 5 and 3, respectively) Times. In comparison with the neutralizing antibody titer against the original strain).However, non-neutralizing antibody responses and T cell responses Found to be comparable Between WA1/2020 and variants B.1.1.7, B.1.351, P.1 and CAL.20C.
“Given the protective efficacy of the vaccine, as shown in phase 3 clinical trials, non-neutralizing antibodies and/or T cell responses may help prevent COVID-19“Researchers pointed out A note, Refer to the published efficacy data, which shows Strong protection From the symptomatic form of Covid-19 in trials conducted in South Africa and Brazil, most of the Covid-19 cases sequenced were caused by the mutation of the virus. In general, scholars have noticed that these new results “Help us understand vaccine protection For the most worrying variant SARS-Cov-2 “.
Although the relevance of protection (that is, the level of antibodies and T cells above this level, a person is protected, and below this level, a person is vulnerable to pathogens) has not yet been determined, but the data provides information about the cellular immune system in the following aspects The new information on the role of new information on the protection of diseases has made people aware of the importance of preventing Covid-19 in areas where the relevant mutations are spread. “The strong protective effects of vaccines have been observed in studies in South Africa and Brazil -Commented by Dan Brarouch, an immunologist and director of the Virology and Vaccine Research Center of Beth Israel Deaconess Medical Center- Increase even non-neutralizing antibodies and/or T cell response may help protect. Alternatively, low levels of neutralizing antibodies may be sufficient to provide protection“.